Clinical Trials Logo

Clinical Trial Summary

PhenoDM1 will use patient reported outcomes to assess levels of pain, fatigue and quality of life in this cohort. Clinical and functional outcomes will look at muscle wasting and levels of myotonia. DNA, RNA, serum and CSF samples will be taken from all patients so that additional genetic and molecular biomarker analysis can be carried out. A subset of patients will undergo detailed sleep studies along with skeletal muscle MRI of the lower limbs. This study will complement the work of other groups currently looking at myotonic dystrophy type 1 using the same outcomes and measures where possible.


Clinical Trial Description

Myotonic Dystrophy type I (DM1) is the most common form of adult muscular dystrophy, affecting 1 in 8000 individuals. It is an autosomal dominant disorder with multisystemic involvement of multiple organs and tissues, namely brain, heart, endocrine system, eyes and both smooth and skeletal muscles. It results from the CTG expansion of an untranslated region 3' terminal of the DMPK gene which causes a disturbance of the RNA metabolism, in particular defective splicing of various pre-mRNAs such as the muscular chloride channel (causing myotonia), the insulin receptor (causing diabetes) and others. We will carry out an in-depth characterisation of 400 adult DM1 patients identified from local clinical populations across England and through the national DM Registry. Over a two year period we will take measurements 12 months apart to address specific symptoms that cause major quality of life impairment including muscle weakness, myotonia, excessive daytime sleepiness and cognitive impairment. DNA samples will be collected in order to determine the CTG repeat length and serum samples for biomarker identification. We will carry out muscle MRI and sleep studies in a subset of 50 patients. The implemented measures will capitalise on the efforts of previous cohort studies ensuring that all measures are comparable with existing datasets. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02831504
Study type Observational
Source Newcastle-upon-Tyne Hospitals NHS Trust
Contact
Status Completed
Phase
Start date August 2015
Completion date October 31, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT00082108 - Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Enrolling by invitation NCT05916677 - Virtual Reality-training in Theory of Mind in the Childhood Form of Myotonic Dystrophy Type 1 N/A
Completed NCT02308657 - Multicenter Observational Study of Myotonic Dystrophy Type 1 N/A
Enrolling by invitation NCT06316778 - Pelvic Floor Muscle Training for Women With Myotonic Dystrophy N/A
Completed NCT02312011 - A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 Phase 1/Phase 2
Recruiting NCT02269865 - Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy N/A
Completed NCT00577577 - Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 Phase 2
Recruiting NCT06075693 - Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
Completed NCT02118779 - Observational Prolonged Trial in Myotonic Dystrophy Type 1 N/A